

091-255928

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:
Estimated average burden hours per response: 2.00		

SEC / TM

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

NYSE American, LLC (trading pursuant to unlisted trading privileges)

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

Open-end Management Investment Company

3. Class of New Derivative Securities Product:

Investment Company Units

4. Name of Underlying Instrument:

Solactive Emerging Markets Healthcare Index

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

Narrow-Based

6. Ticker Symbol(s) of New Derivative Securities Product:

KMED

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

KOREA, SHENZHEN, HONG KONG, SHANGHAI, JSE, THAILAND, NASDAQ, BSE INDIA, SAO PAULO, BUDAPEST, MALAYSIA, INDONESIA

8. Settlement Methodology of New Derivative Securities Product:

Regular way trades settle on T+2/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):

Not applicable.

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Clare F. Saperstein

Title:

Associate General Counsel

Telephone Number:

(212) 656-2355

Manual Signature of Official Responsible for Form:

Clare F. Saperstein

August 31, 2018

SEC 2449 (1/99)

SEC Mail Processing

SEP 04 2018

Washington, DC



18010432

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	SEP 04 2018



Via Overnight Mail

August 31, 2018

Ms. Claudette Ransom
US Securities and Exchange Commission
Division of Trading and Markets
Station Place – Building I
100 F Street, N.E. – Room 7010
Washington, DC 20549

Re: 19b-4(e) – Transmittal (NYSE American, LLC)

Dear Ms. Ransom:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

Impact Shares YWCA Women's Empowerment ETF (WOMN)
Global X Adaptive U.S. Factor ETF (AUSF)
Innovator S&P 500 Buffer ETF – July (BJUL)
KraneShares Emerging Markets Healthcare Index ETF (KMED)

If you have any questions, please do not hesitate to call me at (212) 656-2355.

Sincerely,

Clare F. Saperstein
Associate General Counsel

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2355
F + 1 212 656 8101
Clare.Saperstein@theice.com

RECEIVED
2018 SEP -5 AM 7:40
SEC / TM

SEC Mail Processing

SEP 04 2018

Washington, DC

Enclosures